AS 900672-Enriched

Drug Profile

AS 900672-Enriched

Alternative Names: AS900672-Enriched; Follicle-stimulating hormone analogue - Merck Serono; FSH analogue - Merck Serono; Glycosylated recombinant follicle-stimulating hormone; Glycosylated recombinant FSH; Hyperglycosylated FSH - Merck Serono; Long-acting follicle stimulating hormone - Merck Serono; Long-acting FSH - Merck Serono

Latest Information Update: 07 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer EMD Serono
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 30 Sep 2008 Merck KGaA completes a phase II trial for Female infertility in USA (NCT00505752)
  • 03 Jul 2007 Phase I development is ongoing for Female infertility
  • 08 Jan 2007 Serono is now called Merck Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top